Effect of hypoproteinemia on cefoperazone sulbactam plasma concentration
10.12206/j.issn.2097-2024.202309040
- VernacularTitle:低蛋白血症对头孢哌酮舒巴坦血药浓度的影响
- Author:
Jihua ZHAN
1
;
Ying YAN
1
Author Information
1. Department of Pharmacy, Central Hospital of Hengyang, Hengyang 421001, China.
- Publication Type:Medicine&Clinical
- Keywords:
cefoperazone sulbactam;
hypoproteinemia;
clinical efficacy
- From:
Journal of Pharmaceutical Practice and Service
2025;43(7):344-347
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the effect of hypoproteinemia on the use of cefoperazone sulbactam in patients, and provide references for the rational use of cefoperazone sulbactam in clinical practice. Methods Clinical data of patients with cefoperazone blood concentration monitoring in our hospital from July 2021 to March 2022 were collected, and divided into low albumin group and normal albumin group according to different albumin concentration. Statistical analysis were conducted based on gender, age, laboratory examination, cefoperazone valley concentration and clinical efficacy of the two groups. Results Age, gender, inflammation and liver function of two groups had not shown statistical difference （P>0.05）. Low protein group had significantly higher levels of creatinine than those in group with normal albumin （P<0.05）. The trough concentration of cefoperazone in the low protein group was （46.29±36.94） mg/L, and that in the normal albumin group was （38.18±33.79） mg/L. Among the low protein patient group, the plasma concentration of cefoperazone in those treated with human albumin was significantly higher than that in the patients without human albumin treatment （P<0.05）. Comparison of the clinical efficacy of the two groups revealed that the low protein group had a lower clinical response rate （P<0.05）. Conclusion Supplementation of human serum albumin in patients with hypoproteinemia could increase the plasma concentration of cefoperazone, and correcting hypoproteinemia could be helpful for anti-infection treatment.
